Janux Therapeutics, Inc.
JANXNASDAQHealthcareBiotechnology
As of Oct 16, 2026 close
- Market cap
- $1.09B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $12.12$35.34
- Volume (live)
- -
- Avg. volume (3M)
- 905.34K
Janux Therapeutics (JANX) Stock Price & Financial Analysis
Janux Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $16.43 - $17.27 |
|---|---|
| 52-Week High | $35.34 |
| 52-Week Low | $12.12 |
| Open | $17.27 |
| Volume (last close) | 765.88K |
| Average Volume (3M) | 905.34K |
| Revenue (TTM) | 31.88M |
|---|---|
| Net Income (TTM) | -102.59M |
| Free Cash Flow (TTM) | -54.53M |
| EPS (TTM) | −$1.64 |
| Profit Margin | -321.81% |
| Operating Margin | -450.30% |
| Return on Equity (ROE) | -11.06% |
| Debt to Equity | 0.02 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 1.09B |
|---|---|
| Shares Outstanding | 62.94M |
| Price to Sales (P/S) | 34.19 |
| Price to Book (P/B) | 1.17 |
| EV/EBITDA | -9.82 |
| 50-Day MA | $17.44 |
|---|---|
| 200-Day MA | $15.13 |
| 1-Year Change | −35.28% |
Source: Market prices and company fundamentals. Data as of Oct 16, 2026. Data sources and methodology
Janux Therapeutics at a Glance
As of the Oct 16, 2026 close, Janux Therapeutics (JANX) has a market capitalization of $1.09B. The stock trades at 34.2× sales. Over the trailing twelve months it lost $102.59M on revenue of $31.88M and burned $54.53M of free cash flow. Revenue grew 5367.0% year over year.
As of its latest reported balance sheet, it holds $27.77M in cash and securities against $20.99M of debt, a net cash position of $6.78M.
Janux Therapeutics does not currently pay a dividend.
The share price is down 35.3% over the past year. At $16.51 (the Oct 16, 2026 close) it sits within its 52-week range of $12.12 to $35.34, above its 200-day moving average of $15.13.
Based on 12 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $34.22, 107.3% above the Oct 16, 2026 close.
Frequently Asked Questions About Janux Therapeutics
What is the current stock price for JANX?
As of the Oct 16, 2026 close, JANX stock trades at $16.51. The 52-week range is $12.12–$35.34, with a day range of $16.43–$17.27.
What is the P/E ratio for JANX?
The P/E ratio (Price-to-Earnings) for JANX is shown in the Key Statistics section. This valuation metric helps compare Janux Therapeutics, Inc. to industry peers.
Does JANX pay dividends?
Janux Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for JANX?
Based on ratings from 12 professional analysts over the last 90 days, the consensus for JANX is Buy. The average 12-month price target is $34.22, a 107.3% upside from the Oct 16, 2026 close of $16.51.
What is the market cap of JANX?
As of the Oct 16, 2026 close, Janux Therapeutics's market capitalization is $1.04B, classifying it as a small-cap company. Janux Therapeutics operates in the Healthcare sector within the Biotechnology industry.